Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- gilteritinib
- mavacamten
Interactions between your drugs
gilteritinib mavacamten
Applies to: gilteritinib, mavacamten
Mavacamten may reduce the blood levels of gilteritinib, which may make the medication less effective in some cases. Contact your doctor if your symptoms worsen or your condition changes. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
mavacamten food
Applies to: mavacamten
Grapefruit juice may increase the blood levels of mavacamten and increase the risk of heart failure, a condition where the heart is unable to pump blood adequately to meet the body's needs. Your risk may be further increased if you develop a serious infection or irregular heartbeat during treatment with mavacamten. You should avoid the consumption of grapefruit and grapefruit juice while taking this medication. Talk to your doctor if you have any questions or concerns. You should seek medical attention if you experience signs and symptoms of heart failure such as shortness of breath, chest pain, fatigue, swelling in your legs, palpitations, or rapid weight gain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Xospata
Xospata (gilteritinib) is used to treat acute myeloid leukemia (AML) with a FLT3 mutation. Xospata ...
Revuforj
Revuforj is used to treat acute leukemia with a lysine methyltransferase 2A gene translocation ...
Vanflyta
Vanflyta (quizartinib) is an oral targeted treatment called a kinase inhibitor that may be used to ...
Idhifa
Idhifa (enasidenib) is used to treat acute myeloid leukemia in adults who have a mutation in the ...
Onureg
Onureg (azacitidine) is used for the continued treatment of adult patients with acute myeloid ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.